Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
Latest posts by Hippocratic Post (see all)
- Shake-up of services needed to ease fibromyalgia pain - 9th December 2025
- Continuous glucose monitoring reduces risk of excessive birth weight - 9th December 2025
- Significant mental health benefits of adult-worn slings - 9th December 2025